Jade Therapeutics

BioTime, Jade Therapeutics ink deal

Friday, September 20, 2013

BioTime, a biotechnology company that develops and markets products in regenerative medicine, has signed an exclusive sublicense agreement with Jade Therapeutics, a Salt Lake City, Utah-based developer of ophthalmic sustained-release drug delivery platforms. This new agreement supersedes the previously announced sublicense and supply agreements and expands the licensed field of use to include certain additional uses, such as BioTime’s HyStem hydrogel technology for the delivery of all potential therapeutic molecules to the human eye. Excluded from the licensed field of use is the HyStem technology for the delivery of cells with or without any molecules necessary for the therapeutic benefit of those cells, for use in making punctal plugs, for diagnostic and research reagents and for non-human applications.

[Read More]